SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (16816)3/8/1998 10:01:00 PM
From: Abuckatatime  Read Replies (2) | Respond to of 32384
 
Bernie, the 2005 reference came from Message 3156456
and I certainly wouldn't mind if DR had meant to say "even with hands tied behind our backs, 2005 at the latest." Though we're going on scant data at the moment couldn't we assume that the agent under discussion will be highly specific and that the side/adverse effect profile should be no greater than the recombinant-based hematopoietics already in use?



To: Flagrante Delictu who wrote (16816)3/8/1998 10:19:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Bernie, I don't think that it matters. If they are bringing EPO or G-CSF to trial THIS year, then they have already done extensive pre-clinicals on one or both. I think that the G-CSF report at Keystone and Lake Tahoe, was a red herring, or simply a na-na-na-na-na-hah to all other those me toos scrambling at this time.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News